Following PhIII breakdown, AstraZeneca cruises toward an FDA decision for its BTK blockbuster hopeful acalabrutinib
Just when AstraZeneca would prefer to turn away from its Phase III breakdown with durvalumab and tremelimumab, along comes acalabrutinib.
Yesterday, their BTK inhibitor was granted a breakthrough therapy designation at the FDA, and regulators immediately backed it up today with a priority review designation that will speed up the oversight process and quite likely offer another cancer drug approval sometime in January 2018.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
